Last $0.0003 USD
Change Today -0.0001 / -25.00%
Volume 2.2M
MCET On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

multicell technologies inc (MCET) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $0.0027
52 Week Low
12/29/14 - $0.0002
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

multicell technologies inc (MCET) Related Businessweek News

No Related Businessweek News Found

multicell technologies inc (MCET) Details

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprise MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

2 Employees
Last Reported Date: 02/28/14
Founded in 1962

multicell technologies inc (MCET) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

multicell technologies inc (MCET) Key Developments

Multicell Technologies, Inc. to Approve Amendment to Amended and Restated Certificate of Incorporation

MultiCell Technologies, Inc. announced that the annual general meeting to be held on January 22, 2015, to approve an amendment to the Amended and Restated Certificate of Incorporation, as amended, to effect an increase in the number of authorized shares of the company's common stock to a total of 10 billion shares.

MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application

MultiCell Technologies, Inc. has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody. Cancer therapy often results in the patient becoming very sick due to toxicity and off-target effects of certain drugs used to treat patients. ADCs take advantage of the target specificity of a monoclonal antibody to deliver a potent cytotoxic compound selectively to just the targeted tumor cells, thus improving the drug's therapeutic safety window by decreasing the likelihood of adverse off-target effects. As a result of decreasing off-target effects, overall patient experience and patient outcomes are improved. This patent application describes compositions-of-matter, a multivalent biodegradable linker and tether to attach drugs to the antibody or other targeting agents, and the therapeutic use of such drug conjugates to treat cancer and other diseases. These unique ADCs are designed to release drugs in their native form via biodegradation of the novel cleavable, multi-valent linker and tether after the ADC enters the cell.

MultiCell Technologies Inc. Files U.S. and International Patent Applications for the Treatment of Liver Cancer

MultiCell Technologies, Inc. has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in vitro models of hepatocellular carcinoma. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 has demonstrated in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. MultiCell also plans to study MCT-485 in relevant in vitro and animal models for other major cancers. In contrast to other species of RNAs including siRNAs, MCT-485 appears to induce cancer cell death through a biological process called pyroptosis; a caspase 1-dependent self-destruction cell death that involves pro-inflammatory cytokine production. Typically, pyroptosis is triggered by various pathological stimuli. MCT-485 is thought to suppress or modify the amount of mRNA being expressed by various genes linked to the metabolism, proliferation and viability of cancer cells thereby inducing a state of cellular stress within the cancer cell. MCT-485 appears to exert a preferential biological activity on transformed liver cancer cells while showing no effect on normal, non-transformed liver cells.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCET:US $0.00 USD -0.0001

MCET Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCET.
View Industry Companies

Industry Analysis


Industry Average

Valuation MCET Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MULTICELL TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at